WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60

Login

Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :

Download Article: Click Here

Search

Track Your Article

Abstract

FORMULATION, DEVELOPMENTAND EVALUATION OF SUSTAINDED-RELEASE TABLET OF DOXOPHYLLINE

Swati S. Rawat*, Yogesh P. Sharma and Chetan A. Dande

Abstract

Compared to other oral dosage forms, tablets are the manufacturer’s dosage form of choice because of their relatively low cost of manufacture, package, and shipment. the goal of a sustained-release dosage form is to maintain therapeutic blood or tissue levels of drug for an extended period. This is usually accomplished by attempting to obtain zero-order release from the dosage form. Zero-order release constitutes drug release from the dosage form that is independent of the amount of drug in drug delivery system. The matrix system is one of the intricate approaches for the preparation of the sustained release dosage forms and formulation of matrix tablet has gained immense popularity now a day because it has the advantage of simple processing and low cost of fabrication. Formulated oral sustained release matrix tablets of Doxofylline, bronchodilator and anti-asthmatic agent in order to improve efficacy, reduce the frequency of administration, and better patient compliance. Matrix tablet of Doxofylline, prepared using Eudragit L100-55, microcrystalline Cellulose (Avicel PH 101), Pyrollidone K-30, Eudragit NE 30-D, Crosscarmellose Sodium (AC DI SOL), Magnesium stearate can successfully be employed in oral controlled release drug delivery system, as it is likely to increase its GI residence time, and eventually, improve the extent of bioavailability. However, appropriate balancing between various levels of polymers is imperative to acquire proper controlled release of drug. The physicochemical compatibility of the drug with polymers was established through FTIR spectroscopy. All blended formulations were evaluated for bulk density, tapped density, Carr’s index, angle of repose and the Hausner’s ratio. All these results indicated that, the powder blend showed good flow properties. All tablet formulation has their weight within 900 mg for F1 to F5 and 1045 mg for F6 to F10 respectively, and were uniform in diameter. The formulation all trials batch of F1, F5 and batch F10, have the sufficient hardness and friability i.e., with in the limit and dissolution. During experimental studies formulation F10 given best drug release up to the 24 hrs compared to other formulation and it closely matched the dissolution profile of the innovator. Accelerated stability studies results were found within limits. Sustained release tablet of Doxofylline can be successfully employed as, bronchodilator and anti-asthmatic agent.

Keywords: Doxofylline, Eudragit L 100 – 55, Microcrystalline Cellulose(Avicel PH 101) Polyvinyl Pyrollidone K-30, Eudragit NE 30-D, Croscarmellose Sodium(AC DI SOL), bronchodilator, anti-asthmatic agent.


[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More